You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Immune Checkpoint Blockade

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Response to Immune Checkpoint Blockade in Metastatic Melanoma

Completed
  • Melanoma
  • F-FDG PET/CT
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
Jul 7, 2022

Gastrointestinal Cancer Trial in New York, Providence (Cobimetinib, Hydroxychloroquine, Atezolizumab)

Active, not recruiting
  • Gastrointestinal Cancer
  • New York, New York
  • +1 more
Nov 29, 2022

Resectable Hepatocellular Carcinoma Trial (Cadonilimab, TACE, Surgery)

Not yet recruiting
  • Resectable Hepatocellular Carcinoma
  • (no location specified)
Dec 12, 2022

Metastatic Breast Cancer Trial in Amsterdam (Nivolumab, Cisplatin, Low dose doxorubicin)

Recruiting
  • Metastatic Breast Cancer
  • Amsterdam, Netherlands
    Antoni van Leeuwenhoek
Mar 21, 2022

Ovarian Cancer Recurrent Trial in Pittsburgh (Rintatolimod, Pembrolizumab, Cisplatin)

Recruiting
  • Ovarian Cancer Recurrent
  • Pittsburgh, Pennsylvania
    Magee-Womens Hospital of UPMC
Mar 3, 2022

Colonic Tumors, Colorectal Tumors Trial in Detroit, New York, Cincinnati (GRT-C901, GRT-R902, Atezolizumab)

Recruiting
  • Colonic Neoplasms
  • Colorectal Neoplasms
  • Detroit, Michigan
  • +2 more
Aug 1, 2022

Metastatic Extracranial Malignant Solid Tumor, Radiotherapy, Immune Checkpoint Blockade Trial in Shantou (Intestinal Low Dose

Not yet recruiting
  • Metastatic Extracranial Malignant Solid Neoplasm
  • +3 more
  • Intestinal Low Dose Radiotherapy-1Gy
  • +3 more
  • Shantou, Guangdong, China
    Cancer Hospital, Shantou University Medical College
Oct 7, 2023

Primary and Metastatic Tumors in Renal Cell Carcinoma and

Recruiting
  • Renal Cell Carcinoma
  • +4 more
  • Immune checkpoint inhibitor targeting PD1
  • Philadelphia, Pennsylvania
    Fox Chase Cancer Center - Philadelphia
Jan 27, 2023

Advanced Solid Tumors Trial in United States (mRNA-4359, Pembrolizumab)

Recruiting
  • Advanced Solid Tumors
  • mRNA-4359
  • Pembrolizumab
  • San Francisco, California
  • +9 more
Sep 7, 2022

Pancreatic Ductal Adenocarcinoma Trial in New York (Stereotactic body radiotherapy (SBRT), Zimberelimab, Quemliclustat)

Recruiting
  • Pancreatic Ductal Adenocarcinoma
  • Stereotactic body radiotherapy (SBRT)
  • +4 more
  • New York, New York
    Columbia University Irving Medical Center
Sep 15, 2023

A Study of Immunotherapy Treatment in People With Sarcoma

Enrolling by invitation
  • Sarcoma
    • Basking Ridge, New Jersey
    • +6 more
    Oct 27, 2023

    Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma Trial in Tampa (Excerise, Checkpoint Blockade,

    Recruiting
    • Cutaneous Melanoma
    • +2 more
    • Excerise
    • Checkpoint Blockade, Immune
    • Tampa, Florida
      Moffitt Cancer Center
    Sep 21, 2022

    Glioblastoma Trial in Saint Louis (NeoVax, Nivolumab, Ipilimumab)

    Terminated
    • Glioblastoma
    • NeoVax
    • +4 more
    • Saint Louis, Missouri
      Washington University School of Medicine
    Oct 26, 2021

    Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma Trial in

    Not yet recruiting
    • Clinical Stage III Cutaneous Melanoma AJCC v8
    • +4 more
    • Nashville, Tennessee
      Vanderbilt University/Ingram Cancer Center
    Feb 28, 2023

    Glioblastoma Trial in Atlanta, Bethesda (Nivolumab, BMS-986016)

    Recruiting
    • Glioblastoma
    • Atlanta, Georgia
    • +1 more
    Sep 21, 2022

    Epithelial Tumors, Malignant, Malignant Solid Tumor Trial in Barcelona (NEXTGEN-TIL, Non-myeloablative Lymphodepletion (NMA-LD)

    Recruiting
    • Epithelial Tumors, Malignant
    • Malignant Solid Tumor
    • NEXTGEN-TIL
    • +2 more
    • Barcelona, Spain
      Vall d'Hebron Institute of Oncology
    Nov 25, 2021

    Sarcomas, Melanomas, Germ Cell Tumors Trial run by the NCI (AeroEclipse II Breath Actuated Nebulizer, Bintrafusp alfa,

    Withdrawn
    • Sarcomas
    • +4 more
    • AeroEclipse II Breath Actuated Nebulizer
    • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Dec 16, 2021

    Solid Cancers Trial in Toulouse (Patients treated with immune checkpoint blockade)

    Recruiting
    • Solid Cancers
    • Patients treated with immune checkpoint blockade
    • Toulouse, France
    • +1 more
    Mar 28, 2022

    Malignant Melanoma Trial in Aurora (Oral Decitabine/Cedazuridine (DEC-C) in Combination with Nivolumab)

    Recruiting
    • Malignant Melanoma
    • Oral Decitabine/Cedazuridine (DEC-C) in Combination with Nivolumab
    • Aurora, Colorado
      University of Colorado Hospital
    May 25, 2022

    Pancreatic Cancer, Adenocarcinoma of the Pancreas, Adenocarcinoma Trial in New York, Providence (Motixafortide, Cemiplimab,

    Recruiting
    • Pancreatic Cancer
    • +2 more
    • New York, New York
    • +1 more
    Nov 7, 2022

    Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint

    Recruiting
    • Pneumonitis, Interstitial
    • +2 more
    • Immune checkpoint blockade
    • +2 more
    • Leuven, Flemish Brabant, Belgium
      Universitaire Ziekenhuizen Leuven
    Mar 18, 2021

    Metastatic Cancer, Melanoma Cancer, Lung Cancer Trial in United States (Stereotactic Body Radiotherapy, Ipilimumab, Nivolumab,

    Recruiting
    • Metastatic Cancer
    • +5 more
    • Stereotactic Body Radiotherapy
    • Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab
    • Hartford, Connecticut
    • +9 more
    Nov 17, 2022

    Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor Trial in Chengdu (lenvatinib

    Enrolling by invitation
    • Hepatocellular Carcinoma Non-resectable
    • +3 more
    • lenvatinib + sindilimab/carrelizumab
    • TACE
    • Chengdu, Sichuan, China
      West China Hospital of Sichuan University
    May 23, 2022

    Sarcoma, HER-2 Protein Overexpression Trial in Houston (cells, Pembrolizumab Injectable Product, Nivolumab Injectable Product)

    Recruiting
    • Sarcoma
    • HER-2 Protein Overexpression
    • cells
    • +3 more
    • Houston, Texas
      Texas Children's Hospital
    Dec 8, 2021

    Hepatocellular Carcinoma, Solid Tumor, Hepatocellular Carcinoma Non-resectable Trial in San Antonio (OTX-2002, Tyrosine kinase

    Not yet recruiting
    • Hepatocellular Carcinoma
    • +6 more
    • San Antonio, Texas
      Next Oncology
    Aug 9, 2022